The US Federal Trade Commission (FTC) wants to clear the takeover of Irish biotech company Horizon Therapeutics by pharmaceutical group Amgen. Following concessions by Amgen, the authority is dropping its earlier objections to the $27.8 billion purchase, the FTC announced last Friday.
The US Federal Trade Commission’s lawsuit to potentially block the $27.8 merger of Amgen and Horizon Therapeutics is creating heightened concern in the international biopharma sector.
The Federal Trade Commission (FTC) has asked a US federal judge to hold “pharma bro” Martin Shkreli in contempt for forming another drug company that it said violates a January 2022 court order that banned him from working in the pharmaceutical industry
